Abstract
This patient was found to have a BRCA2 gene mutation. She underwent lumpectomy and axillary lymph node dissection without any evidence of lymph node metastasis. Systemic chemotherapy with doxorubicin and cyclophosphamide for four cycles was administered beginning in the second trimester. She was treated with prophylactic LMWH until delivery and then for 6 weeks postpartum. She delivered a healthy baby boy and, after a period of breast-feeding, underwent bilateral mastectomy with immediate reconstruction. She remains well and is expecting her second child. Prophylactic oophorectomy is planned after completion of this pregnancy.
MeSH terms
-
Adult
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Apoptosis Regulatory Proteins
-
BRCA2 Protein / genetics*
-
Breast Neoplasms / diagnosis*
-
Breast Neoplasms / drug therapy
-
Breast Neoplasms / genetics
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Female
-
Humans
-
Infant, Newborn
-
Lymph Node Excision
-
Male
-
Mastectomy, Segmental
-
Pregnancy
-
Pregnancy Complications, Neoplastic / diagnosis*
-
Pregnancy Complications, Neoplastic / drug therapy
-
Pregnancy Complications, Neoplastic / genetics
-
Pregnancy Trimester, First
-
Pregnancy Trimester, Second
-
Prognosis
-
Thrombophilia / complications
-
Thrombophilia / diagnosis*
Substances
-
Apoptosis Regulatory Proteins
-
BLID protein, human
-
BRCA2 Protein
-
BRCA2 protein, human
-
Doxorubicin
-
Cyclophosphamide